Small subcortical strokes (S3) also known as lacunar strokes, are a common stroke subtype accounting for at least 25% of all ischemic strokes. In Hispanic Americans, S3 are a frequent stroke subtype and occur at a relatively young age. S3 are usually due to small vessel disease, a common substrate for vascular dementia. Over two million survivors of S3 are at risk for recurrent stroke and for vascular dementia;millions more suffer sub-clinical S3 and cognitive decline caused by small vessel disease. Secondary Prevention of Small Subcortical Strokes (SPS3) is an international randomized, multicentre clinical trial testing two interventions in a factorial design. It will enroll 3000 participants (20% of whom will be Hispanic Americans) with symptomatic, MRI-defined S3 without carotid stenosis or major cardio-embolic sources. Patients are assigned, in a factorial design, to two interventions: 1. Antiplatelet Intervention: 325 mg/d vs. aspirin 325 mg/d plus clopidogrel 75 mg/d. 2. Blood Pressure Invention: systolic blood pressure targets of 130 to 149 mmHg vs. <130 mmHg. The antiplatelet comparison is double-blinded, while the blood pressure intervention is open- label with blinded assessment and verification of clinical events. Follow-up is every three months for a mean of 3 years. Main study outcomes are: 1) recurrent stroke (ischemic and hemorrhagic), 2) cognitive decline, 3) major vascular events The key hypotheses for SPS3 are: 1. Combination antiplatelet therapy is more efficacious than aspirin alone for prevention of stroke recurrence and for reduction in cognitive decline. 2. Intensive blood pressure control is associated with fewer recurrent strokes and reduction in cognitive decline. 3. The absolute reduction in stroke and cognitive decline will be greater in Hispanic Americans vs. non-Hispanic white participants. As of November 1, 2010, 2865 patients were enrolled in 66 currently active clinical sites. No previous randomized trials have focused specifically on secondary prevention of stroke after S3, on optimal target levels of blood pressure control after stroke and their relationship to cognitive decline, or on prevention of stroke and dementia in Hispanic Americans. The results of SPS3 will likely lead to important reductions in the burden of serious neurological diseases (stroke and vascular dementia) for millions of people with S3, and particularly for Hispanic Americans. The study objectives remain unchanged from the original application. The purpose of this application is to request support for continuation and completion of the trial necessitated by the increase in sample size of 500 participants and an additional year of follow up for all subjects in order to accrue the required number of primary events.

Public Health Relevance

At least 200,000 small subcortical strokes (S3) occur annually in the U.S., with nearly two million S3 survivors at high risk for recurrent stroke and vascular dementia. It remains unclear how to optimally prevent stroke recurrence and cognitive impairment in this population. SPS3 will address several important clinical and scientific questions by testing two interventions in patients with recent MRI-defined S3. The results will inform the management of millions of patients with this common vascular disorder.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of British Columbia
Zip Code
V6 1-Z3
McClure, Leslie A; Szychowski, Jeff M; Benavente, Oscar et al. (2016) A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study. Clin Trials 13:537-44
Odden, Michelle C; McClure, Leslie A; Sawaya, B Peter et al. (2016) Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 67:63-9
Boehme, Amelia K; McClure, Leslie A; Zhang, Yu et al. (2016) Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study. Stroke 47:659-67
Field, Thalia S; McClure, Leslie A; White, Carole L et al. (2015) Should Blood Pressure Targets After Lacunar Stroke Vary by Body Size? The SPS3 Trial. Am J Hypertens 28:756-64
Jacova, Claudia; Pearce, Lesly A; Roldan, Ana M et al. (2015) Cognitive performance following lacunar stroke in Spanish-speaking patients: results from the SPS3 trial. Int J Stroke 10:519-28
Zhu, Shuhan; McClure, Leslie A; Lau, Helena et al. (2015) Recurrent vascular events in lacunar stroke patients with metabolic syndrome and/or diabetes. Neurology 85:935-41
Field, Thalia S; Pearce, Lesly A; Asinger, Richard W et al. (2015) Left Ventricular Geometry on Transthoracic Echocardiogram and Prognosis after Lacunar Stroke: The SPS3 Trial. J Stroke Cerebrovasc Dis 24:1423-9
White, Carole L; Szychowski, Jeff M; Pergola, Pablo E et al. (2015) Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experience. J Am Geriatr Soc 63:722-9
McDonough, Caitrin W; McClure, Leslie A; Mitchell, Braxton D et al. (2015) CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc 4:e001652
Nakajima, Makoto; Pearce, Lesly A; Ohara, Nobuyuki et al. (2015) Vertebrobasilar ectasia in patients with lacunar stroke: the secondary prevention of small subcortical strokes trial. J Stroke Cerebrovasc Dis 24:1052-8

Showing the most recent 10 out of 45 publications